Group 1: Sales Channel Optimization - The company has streamlined its offline sales channels, retaining high-quality and substantial distributors to meet long-term development needs [2] - Future plans include expanding the number and scale of distributors to enhance market penetration and product share [2] - The company aims to provide comprehensive support to distributors, fostering a robust and efficient offline sales network for mutual benefits [2] Group 2: Sales Performance and Targets - The specific products with sales exceeding 100 million for 2025 will be disclosed in the annual report, but past performance of major products has met expectations [2] - Both online and offline sales channels are critical, with strict internal sales targets set for each channel, which have dedicated teams aiming for strong performance in 2026 [3] Group 3: Channel Coverage and Profitability - The OTC channel currently has low coverage but significant potential, with plans to expand the sales team and improve coverage in 2026 [3] - Among e-commerce platforms, Douyin focuses on brand marketing while Tmall emphasizes product sales, with Tmall showing higher profit margins [3] - JD.com has demonstrated impressive performance in the first three quarters of 2025, and the company plans to deepen cooperation with JD.com to leverage its potential [3] Group 4: New Product Development - The company has registered two new cosmetic raw materials: "Feruloyl Tripeptide-129 Amide" and "Acetylated Tyrosine D-Glutamyl Tripeptide-110 Amide," which will be used for future product development [3]

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company is expected to achieve a turnaround in profitability in 2025, with a projected net profit of 240 to 290 million yuan, compared to a loss of 830 million yuan in the previous year. The adjusted net profit excluding non-recurring items is forecasted to be between 38 to 56 million yuan, up from a loss of 840 million yuan in the prior year [1]. - The anticipated profitability is attributed to the implementation of a focused operational strategy, enhanced brand marketing, and improved product mix leading to higher gross margins. Additionally, gains from financial assets and investment income are expected to contribute positively [1]. - The company plans to focus on core brands and high-margin product categories, increasing marketing investments and enhancing online channel capabilities. Specific strategies include strengthening the product lineup for the Baicaoji brand and improving operational efficiency across various sales channels [2]. Financial Projections - Revenue forecasts for 2025 to 2027 are adjusted to 6.349 billion, 7.075 billion, and 7.798 billion yuan, respectively. Net profits are projected to be 269 million, 402 million, and 527 million yuan for the same period [3][5]. - The company is expected to see a revenue growth rate of 11.8% in 2025, followed by 11.4% in 2026 and 10.2% in 2027. The net profit growth rates are forecasted at 132.2%, 49.8%, and 31.1% for the respective years [5].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 50.56 [1][5]. Core Insights - The main brand, Winona, has been actively streamlining its SKU and refocusing resources on key products since the second half of 2024. There are signs of price stabilization starting mid-2025, and online GMV began to recover in Q4 2025, indicating positive results from reduced inefficient spending and product structure optimization. Cash flow has significantly improved, and there are signs of recovery in profitability [1][5][6]. - The multi-brand strategy is progressing steadily, with core sub-brands like Winona Baby and Aikeman showing high growth in online GMV since Q4 2025. The brand matrix is becoming increasingly comprehensive due to external investments [1][5][8]. Financial Performance - Revenue for the main brand Winona reached RMB 5.2 billion in 2023, but faced pressure in 2024 due to inventory adjustments and product structure changes, with revenues of RMB 4.91 billion and RMB 1.95 billion in the first half of 2024 and 2025 respectively, reflecting year-on-year declines of 5.5% and 18.4% [6][8]. - The company’s gross margin improved to 74.33% in the first three quarters of 2025, with a year-on-year increase of 0.6 percentage points, attributed to maintaining stable pricing and reducing promotional expenses [7]. - The net cash flow from operating activities for the first three quarters of 2025 was RMB 442 million, a significant increase compared to RMB 6 million in the same period of 2024 [7]. Earnings Forecast and Valuation - The company’s net profit attributable to the parent company is forecasted to be RMB 515.4 million in 2025, with an EPS of RMB 1.22. The projections for 2026 and 2027 are RMB 670.97 million (EPS of RMB 1.58) and RMB 786.7 million (EPS of RMB 1.86) respectively [4][9]. - The company is assigned a PE ratio of 32x for 2026, with a target price of RMB 50.56 based on expected revenue and profit recovery [9].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 50.56 [1][5]. Core Insights - The main brand, Winona, has been actively streamlining its SKU and focusing resources on key products since the second half of 2024. There are signs of price stabilization starting mid-2025, and online GMV began to recover in Q4 2025, indicating positive results from reduced inefficient spending and optimized product structure. Cash flow has significantly improved, and there are signs of recovery in profitability [1][5]. - The multi-brand strategy is progressing steadily, with core sub-brands like Winona Baby and Aikeman showing high growth in online GMV since Q4 2025. The brand matrix is becoming increasingly comprehensive due to external investments [1][5]. Financial Performance - Revenue for the main brand Winona reached RMB 5.2 billion in 2023, but faced pressure in 2024 due to inventory adjustments and product structure changes, with revenues of RMB 4.91 billion and RMB 1.95 billion in the first half of 2024 and 2025 respectively, reflecting year-on-year declines of 5.5% and 18.4% [6]. - The gross margin for the company was 74.33% in the first three quarters of 2025, showing a year-on-year increase of 0.6 percentage points, attributed to stable pricing strategies and reduced promotional expenses [7]. - The company’s net cash flow from operating activities was RMB 442 million in the first three quarters of 2025, compared to only RMB 6 million in the same period of 2024 [7]. Growth Projections - The company forecasts net profit attributable to the parent company for 2025, 2026, and 2027 to be RMB 515.4 million, RMB 670.97 million, and RMB 786.7 million respectively, with corresponding EPS of RMB 1.22, RMB 1.58, and RMB 1.86 [9]. - The expected revenue growth rates for 2025, 2026, and 2027 are projected at -4.47%, 12.32%, and 10.05% respectively [4]. Brand Development - Winona Baby is focusing on the sensitive skin segment for infants, achieving an online GMV of RMB 90.7 million in Q4 2025, a year-on-year increase of 21.1%. Aikeman continues to leverage its anti-aging research advantages, with online sales reaching RMB 14.5 million in Q4 2025, a staggering year-on-year increase of 736.5% [8]. - The company has been actively expanding its brand portfolio through strategic investments, including a stake in a makeup brand and a medical beauty device company, enhancing its presence in the beauty and personal care sectors [8].

Group 1 - Guangzhou is a significant hub for China's animation and gaming industry, hosting numerous enterprises and institutions involved in content creation and commercial monetization [1][3] - The "Beautiful Career, Beautiful Life" beauty training project by L'Oréal China aims to empower women by integrating public welfare training with local industry needs, focusing on the emerging profession of Cosplay makeup artists [2][4] - There is a growing demand for professional makeup artists ("Zhuang Niang") and prop makers in the Cosplay sector, driven by an influx of young enthusiasts into the community, indicating a need for standardized and professional talent development [3] Group 2 - The China Women's Development Foundation has collaborated with L'Oréal China to support over 14,600 women in urban and rural areas over the past decade, emphasizing the integration of public welfare training with local industry demands [4] - The training program aligns with national development strategies and leverages Guangzhou's strengths in digital cultural and creative industries, representing an innovative upgrade in the public welfare model [4]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, with dietary intake often insufficient to meet effective dosage levels; NMN supplements provide a much higher intake efficiency [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][12]. - Leading companies are innovating in full enzyme technology, establishing patents to create competitive advantages in the NMN market [12]. Market Trends and Applications - NMN is primarily used in health supplements and cosmetics, with potential expansion into pet nutrition, medical health, and agricultural technology [24][28]. - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by policy relaxation and new applications [28]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification and Compliance - The "blue hat" certification for health supplements in China represents the highest standard for NMN products, with strict approval processes impacting market dynamics [37]. Future Prospects - The NMN industry is poised for growth, with increasing demand driven by an aging population and younger consumers seeking anti-aging solutions [19][21]. - Technological advancements in synthesis, quality control, and delivery methods are expected to enhance NMN's market position [21][22]. Challenges - The NMN industry faces challenges related to regulatory compliance, market education, and technological advancements, necessitating a collaborative approach among stakeholders [61][63].

Core Viewpoint - The article highlights the regulatory chaos surrounding "exosomes" in the medical beauty industry, revealing issues such as unauthorized certifications, false advertising, and illegal injections, which pose risks to consumer safety and market integrity [2][3][4]. Regulatory Issues - Multiple companies have been accused of using medical device licenses to produce exosome products, some of which falsely claim to treat conditions like epilepsy and diabetes, but are actually "three-no products" (no approval, no production, no quality guarantee) [2][4]. - The regulatory framework for exosomes is still being developed, with no exosome drugs approved for market as of March 15, 2026, despite the rapid market growth [4][5]. Market Trends - The incident reflects a deeper transformation in the beauty and medical aesthetics industry, where concepts from medical and biotechnology fields are rapidly entering the consumer market, leading to potential risks as technology outpaces regulation [4][5][6]. - The blending of medical beauty and lifestyle beauty is accelerating, with a growing number of medical concepts being marketed as skincare solutions, raising concerns about consumer safety and product efficacy [5][13]. Consumer Trust and Regulatory Changes - The March 15 exposé serves as a wake-up call for the industry, emphasizing the need for regulatory, scientific, and compliance systems to keep pace with evolving technology narratives [5][19]. - As the regulatory landscape tightens, the beauty industry is shifting towards a focus on trust, with consumers becoming more discerning about product claims and safety [5][19][22]. Data Insights - In recent years, the number of non-compliant cosmetic products has decreased significantly, with the number of problematic batches dropping from 601 in 2023 to 324 in 2025, indicating improved regulatory enforcement [15][17]. - Despite the reduction in regulatory issues, consumer complaints regarding false advertising and product quality have surged, suggesting a shift in consumer focus towards trust and transparency [18][19]. E-commerce and Marketing Regulations - New regulations in 2026 clarify the responsibilities of platforms, operators, and influencers in live commerce, aiming to combat false advertising and ensure consumer protection [26][27]. - The introduction of strict guidelines for live commerce and private domain marketing indicates a move towards greater accountability in the beauty industry [26][29]. Medical Aesthetics and Compliance - The medical aesthetics sector is facing increased scrutiny, with regulations prohibiting unlicensed institutions from performing medical procedures and requiring traceability for medical devices [29][30]. - The challenges posed by unregulated "black technology" in medical aesthetics highlight the need for robust regulatory frameworks to ensure consumer safety [30][31].

Investment Rating - The industry investment rating is "Positive" (maintained) [4] Core Insights - High-end consumption is experiencing a structural transformation, with a slight decline in spending among China's elite consumers, primarily influenced by the macroeconomic environment. Future declines in spending are expected to slow down [4][8] - The luxury goods market shows signs of recovery, with the second-hand luxury market performing strongly. The sales decline in the personal luxury goods market is projected to narrow to 3%-5% in 2025 [4][11][15] - High-end consumption segments such as outbound travel, high-end commercial real estate, luxury hotels, and cosmetics are showing robust growth, indicating a recovery in consumer spending [4][19][22][30][38] Summary by Sections High-end Consumption Insights - The elite consumer group in China, defined as individuals aged 18-55 with an annual income above 200,000 yuan, is experiencing a slight decrease in high-end spending, influenced by macroeconomic factors. However, spending on high-end experiences and services is increasing, reflecting a shift towards self-expressive consumption [4][8] Luxury Goods Market - The luxury goods market is showing recovery signs, with a projected sales decline narrowing to 3%-5% in 2025. Quarterly sales in 2025 are expected to stabilize, with growth in the latter half of the year [4][11][15] - The second-hand luxury market is expected to grow by 15%-20% in 2025, indicating strong demand [15] High-end Consumption Segments - **Outbound Travel**: There is a strong willingness to travel abroad, with a record 697 million inbound and outbound trips in 2025, a 14.2% increase year-on-year [19][20] - **High-end Commercial Real Estate**: Retail properties are showing strong sales performance, with notable growth in retail sales for companies like Swire Properties and Hang Lung Properties [26][27] - **Luxury Hotels**: Marriott's performance in Greater China is recovering, with RevPAR showing positive growth by Q4 2025 [30] - **Duty-Free Shopping**: The duty-free shopping market in Hainan is recovering, with significant growth in shopping amounts in the latter part of 2025 [36][37] - **Cosmetics**: The high-end cosmetics segment is expected to grow faster than the mass market, with projected CAGR of 9.6% for skincare and 10.8% for makeup from 2023 to 2028 [38][40] Gaming and Entertainment - The gaming sector is experiencing a recovery, with Macau's gross gaming revenue (GGR) showing positive growth, driven by increased visitor numbers and entertainment events [54][55]

Sales Goals and Performance - The company has set internal sales targets for 2026, which will not be disclosed externally, and is optimistic about achieving good performance based on refined operations in 2025 [2] - The sales ratio of online to offline channels has improved from 80:20 in the 2025 semi-annual report, with further details to be revealed in the 2025 annual report [2][3] - The company reported good performance during the 3.8 promotional event, aligning with expectations, and aims to enhance sales through active participation in platform activities [3] Product Development and Innovation - The company has a robust pipeline of new products for 2026, including various forms such as dressings, masks, lotions, creams, and serums, with specifics to be confirmed based on actual launches [3] - The R&D team has expanded significantly compared to early 2025, with improvements in the educational background of its members [3] Profitability and Business Strategy - The company plans to strengthen its offline business in 2026, which has a higher net profit margin compared to online sales, and is confident in achieving better overall profitability [3] - The company is considering stock incentive plans but has not set a specific timeline for implementation, with future updates to be disclosed in accordance with regulatory requirements [3] Dividend and Financial Planning - The dividend plan for the current year has not yet been determined, and stakeholders are advised to monitor announcements scheduled for April 23, 2026 [3] General Information - The investor relations activity did not involve any major information that needs to be disclosed [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 130.88 [1] Core Insights - The company has announced a positive earnings forecast for 2025, projecting revenue between CNY 2.4 billion to CNY 2.45 billion, representing a year-on-year increase of 98.4% to 102.5% [6] - The net profit attributable to shareholders is expected to be between CNY 356 million to CNY 361 million, reflecting a year-on-year growth of 90.5% to 93.2% [6] - Adjusted net profit is forecasted to be between CNY 396 million to CNY 401 million, indicating a year-on-year increase of 119.8% to 122.5% [6] - The company is focusing on high-end anti-wrinkle products and has a clear brand positioning, which is expected to drive steady growth [6] Revenue and Profit Forecast - Revenue projections for 2025 are set at CNY 2,421 million, with a growth rate of 100.14% [5] - The adjusted net profit for 2025 is estimated at CNY 398.96 million, with a growth rate of 99.24% [5] - The company anticipates a net profit margin of 16.5% for 2025, which is an increase from the previous year [10] Channel Strategy and Performance - The company is expanding its offline store network, with offline revenue for the first half of 2025 reaching CNY 363 million, a year-on-year increase of 51.5% [7] - The number of stores has increased to 554, with 366 being direct-operated [7] - Online sales, particularly through the Douyin channel, are also showing strong growth, contributing to the overall revenue increase [7] Product Development and Market Position - The company continues to innovate within its core skincare segment, with its flagship product, the essence oil, achieving a GMV growth of 157% in 2025 [8] - New products, such as the "Little Gold Pearl" water, have gained significant market traction, achieving over CNY 10 million in GMV within the first month of launch [8] - The product matrix is being diversified with new SKUs, enhancing market competitiveness [8] Customer Base Expansion - The company is effectively attracting new customer segments through multi-channel outreach and brand value communication [9] - Collaborations with KOLs and KOCs have been instrumental in expanding brand reach and customer engagement [9] Valuation and Market Position - The company’s revenue forecasts for 2025-2027 have been adjusted upwards, reflecting structural growth opportunities in its market segment [10] - The adjusted PE ratio for 2026 is projected at 28x, with a target price maintained at HKD 130.88 [10]